zilongwang/ReadingBank huggingface dataset:
Use Case / Scenarios – SILVER Requirements for ‘Silver’ level service to support messaging, collaboration and unified communication solutions are listed in the table below. Use Case / Scenarios Configuration management Tier 0 applications Tier 1 applications Tier 2 applications Tier 3 applications Tier 4 applications Disaster recovery Data replication Auditing & investigation Moves , additions & changes Performance & latency Remote management / Remote wipe Application packaging BYOD capability Backup & restore Device hygiene Task Worker ? ? Knowledge (Office) Worker Knowledge (Mobile) Worker Field (Mobile) Worker Use Case / Scenarios Security management Service management
Tier 0 applications Tier 1 applications Tier 2 applications Tier 3 applications Tier 4 applications Disaster recovery Data replication Auditing & investigation Moves, additions & changes Performance & latency Remote management / remote wipe Application packaging BYOD capability Backup & restore Device hygiene Task Worker ? ? Knowledge (Office) Worker Knowledge (Mobile) Worker Field (Mobile) Worker Use Case / Scenario Security management Service management Onshore/offshore management Password protection / User authentication Information classification & labelling Role-based security Self-service administration Full service administration Any compliant data centre NSW Government Data Centre Service level management Multi-service broker provision
Quality Control Requirements Quality characteristic Test method Minimum sampling and testing frequency Requirement Sampling location Maximum reporting time allowance Water sulfates a (ppm, max) California Test 417 1 per source 1,300 Source Before work starts Water chlorides a (ppm, max) California Test 422 1 per source 650 Source Gradation (%, passing) b Size 3 inch 2 inch 1.5 inch California Test 202 Test and 1 per lot 100 95-100 85-100 Loose mix after pulverizing and before mixing 24 hours Passing No. 200 sieve (%, max) California Test 202 Test strip and 1 per lot 20 c Loose mix after pulverizing and before mixing 24 hours Sand equivalent (min) California Test 217 Test strip and 1 per lot 25 c mix after pulverizing and before mixing 24 hours Moisture content (%) ASTM D 4643 Test strip and 1 per lot From 99 to 101% of mix design requirement Loose mix after pulverizing and before mixing d 24 hours Engineered emulsion properties Section Each load delivered Section From delivery truck at the job site 24 hours Indirect tensile strength (psi, min) ASTM D 4867 e Test 90% of mix design requirement Loose mix after mixing engineered emulsion 5 business days Laboratory maximum wet density (lb/cu ft) California Test 216 Test strip and 2 per day Use for relative compaction calculation Same location as a California Test 231 location 24 Relative compaction (%, min)(wet density) California Test 231 Test strip and 1 per lot 97 Compacted FDR-E 24 hours a Only required for non-potable water sources. b Remove solids larger than 3 inches. Every 9,000 sq yd, report percent passing the 2”, 1.5”, No. 4, No. 100, and No. 200 sieves. c If test recommend an adjustment in the engineered emulsion content. d Also test compacted material at the end of work shift at the same location, report only. e Report the average of 2 tests from a single sample. For field ITS, immediately compact using a Marshall hammer, 75 blows per face or a superpave gyratory compactor under AASHTO T 312 at 30 gyrations.
Initial ED Vitals – Pulse Rate Initial ED Vitals – Respiration Rate Initial ED Vitals – SBP/DBP Initial ED Vitals – GCS Eye Initial ED Vitals – GCS Verbal Initial ED Vitals – GCS Motor Initial ED Vitals – GCS Total Initial ED Vitals – RTS Procedure Name Start Date/Time AIS Code/Description Injury Severity Score (ISS) Pregnancy Status Discharge Status Discharge or Death Date/Time Total ICU Days Total Ventilator Days Total Hospital Days Discharged To If Transferred, Facility and If Other, Facility Name Transfer Rationale Location of Death QA Filter Code TRISS Record Complete Date and Time Transport Provider arrived at patient Was Patient Extricated Time required( for Patient Extrication) Referring Facility 1 – Arrival Date and Time Referring Facility 2 – Arrival Date and Time Inter-facility Transport Agency (1) – Arrived at Patient: Date and Time Inter-facility Transport Agency (2) – Arrived at Patient: Date and Time AIS Body Region Other/Comments
firewall update inside the cluster, vSfwd demon will parse it but only the ESXi host run VM name will applied rule id 1005. “Applied To” benefits: Reduce the amount of per VMware-sfw, this improves efficiency because the DFW will have less rules to evaluate for every new session. In case of an overlap IP address within multi-tenancy environment we must use “Applied To” to distinguish between one tenant and others. Cross cluster vMotion with “Apply To”: When we do use the “Applied To” feature and the VM traffic perform a vMotion across clusters then the NSX Manger will be involved in the process to update destination VM cluster with the relevant firewall rules. The NSX manager must be up to complete this operation. For example VM name web-sv-01a need to vMotion from “Compute cluster A” to “Management Edge Cluster”, vCenter will send vMotion notification to NSX Manager, as a results NSX Manager will trigger policy push to all ESXi host in “Management Edge Cluster”. web-sv-01a will get same rule before vMotion with just change in the domain object from “domain-c25” to “domain-c7” If the NSX Manager is down, No update rule will be push! When VM land on destination cluster no VM specific rule apply for that VM. It’s important to note that when the NSX manager is down all existing VM’s forwarding plane with DFW rules continue to work, only “New” VMs cannot have firewall rules until NSX Manager come back. The NSX DFW the rule table as a “.dat” file at the ESXi host at the following path: /etc/vmware/vsfwd/vsipfw_ruleset.dat . NSX L2 to L4 Firewall: The VMware NSX DFW can enforce security policy from L2 (Data Link Layer) to L4 (Transport Layer). With L2 we can create DFW rules base on the MAC address or L2 protocol like: ARP,RARP,LLDP.
In the VM’s summary page we can see the security tags that are applied to this VM and to which security group this VM belongs. From the “web-sv-01a” example: Security Policy: Using security policy we can create templates containing DFW policy approved security admin this is “how you want to protect” your environment, then apply this on security groups “WHAT you want to protect”. Security policy may contain traffic redirection rules to 3rd-party vendors for service chaining. Security policy is part of the service composer building blocks. We can a security policy to more than one security group. In the example below we apply “Web Security Policy” to both “Security Group 1” and Security Group 2”. A different option is to two different security policies to same security groups. This can result in a contradiction between the policies. For example we “Security Policy 1” and “Security Policy 2” to “WEB Security Groups”: The security policy precedency will be with a “Weight” value, configured by the security admin. In the following example we demonstrate this when we create two different security policies: “Allow ICMP SP” and “Allow HTTP SP” and apply both to the previously created security group “Web Servers”. Create “Allow ICMP SP”:
smoothing kernel, 2.3 feature selection thresholded, no low-pass filter, and four test-trials per iteration – were subsequently used in the analysis of the validation set. Supplementary Figure 3: Confusion matrices displaying precision-values yielded by the classification analysis of the optimization dataset with the final set of parameters. Because no permutation statistics were calculated for the optimization set, significance was calculated using a one-sample independent t-test against chance-level classification (i.e. 0.333) for each cell in the diagonal of the confusion matrices. Here, all t-statistics use a degrees of freedom of 12 (i.e. 13 subjects - 1) and are evaluated against a significance level of 0.05, For the diagonal of the self-analysis confusion matrix, all values were significantly above chance-level, all p < 0.0001. For the diagonal of the cross-analysis confusion matrix, both the action (43% correct) and situation (44% correct) classes scored significantly above chance, p = 0.014 and p = 0.0007 respectively. Interoception was classified at chance level, p = 0.99, which stands in contrast with the results in the validation-set.
Province of Nova Scotia IN THE YOUTH JUSTICE COURT Her Majesty the v. NSY Form 125 Revised 08/14 Approved: (Name of Young Person) NOTICE OF APPLICATION Judge D/M/Y _______________________________________________ of _______________________________________________ (name of young person) (address) has been □ charged with □ found guilty of the following offence(s): Case No(s). and Brief Description of Offence(s) Section Date of Offence(s) Place TAKE NOTICE that of , the □ Youth □ Crown □ Provincial Director □ Parent □ Other is applying to the Court for the following: □ To extend the time to complete a youth sentence of [Section 54(10) YCJA] □ To compel the attendance of a young person [Section 56(8) YCJA] □ To review a non-custodial sentence [Section 59 YCJA] □ To transfer a youth sentence to a youth justice court in _____________________________ [Section 57(1) YCJA] □ To receive a youth sentence [Section 63(1)] □ To obtain an order that the young person is liable to an adult sentence if found guilty [Section 64(1)] □ To review the custodial placement of a young person subject to an adult sentence [Section 76(6) YCJA] □ To have a continuation of custody [Section 204(1)] □ Other (include section reference) The grounds for the application are: The application will be made to the Youth Justice Court at , Nova Scotia, on , 20 at _______ ___ m. The young person has the right to be represented by counsel (a lawyer), including the right to apply for Legal Aid. DATED at , Nova Scotia, on , 20 . Distribution: □ Court □ Young Person □ Prosecutor □ Defence Counsel □ Probation/Supervisor □ Parent Applicant
4.1. What do you make of the morphology of χαρήσονται? What person and number is it? What is its location on The Pane? Do you see anything besides the personal ending and the stem? What's the lexical form? it out in Gingrich's Shorter Lexicon or BDAG. 4.2. Who is the speaker in this verse? To whom is he/she speaking? 4.3. For γενέσει, are a lot of words in the lexicon that begin with γεν-. How do you know you've selected the right lexical form? Time spent on Greek this week: ______________ Appendix A: "Carver's Keys to the Declension" Learn the basic endings for masc. and fem. 3rd declension nouns as two words: ς /ος /ι /α ες/ων/σι/ας The neuter endings will be the same as the except for adjustments in accordance with noun rules 2 and 3. The nominative singular form (i.e., lexical form) will indicate what the dative plural form will look like (which will end in an ι and may have a moveable ν). Review the Square of Stops + σ chart. The most important step to take for mastering the 3rd declension, however, is memorizing the genitive singular with your vocabulary. Why? Removing the case ending of the genitive singular will reveal the stem of the word! Once you know the stem of the word, you can predict how it will decline in the other cases in both the singular and plural. Illustration: This is how your 3rd declension vocab cards should look. of card πούς, ποδός, ὁ Back of card foot
EQUAL OPPORTUNITIES MONITORING Date of Birth Gender Male Female Transgender Prefer not to say Ethnicity WHITE English Scottish Welsh British Other If ‘Other’ please Specify MIXED White and Black African White and Black Caribbean White and Asian Other If ‘Other’ please specify ASIAN or ASIAN BRITISH Indian Bangladeshi Pakistani Other If ‘Other’ please specify BLACK or BLACK BRITISH African Caribbean Other If please specify ANY OTHER ETHNIC GROUP (please state) Sexual Orientation Bisexual Heterosexual Homosexual Prefer not to say Religious Beliefs Catholic (all) Christian (all) Muslim Hindu Judaism None If ‘Other’ please specify Do you consider yourself to have a disability as defined in current legislation? Under current legislation, a disability is defined as a physical or mental impairment that has a substantial an long-term adverse effect on his or her ability to carry out day to day activities. In this definition, long term is taken to mean more than twelve months and would cover long term illness such as cancer and HIV or mental health problems Yes No
EQUAL OPPORTUNITIES MONITORING Date of Birth Gender Male Female Transgender Prefer not to say Ethnicity English Scottish Welsh Irish British Other If ‘Other’ please Specify MIXED White and Black African White and Black Caribbean White and Asian Other If ‘Other’ please specify ASIAN or ASIAN BRITISH Indian Bangladeshi Pakistani Other If ‘Other’ please specify BLACK or BLACK BRITISH African Caribbean Other If ‘Other’ please specify ANY OTHER ETHNIC GROUP (please state) Sexual Orientation Bisexual Heterosexual Homosexual Prefer not to say Religious Beliefs Catholic (all) Christian (all) Muslim Hindu Judaism Other None If ‘Other’ please specify Do you consider yourself to have a disability as defined in current legislation? Under current legislation, a disability is defined as a physical or mental impairment that has a substantial an long-term adverse effect on his or her ability to carry out day to day activities. In this definition, long term is taken to mean more than twelve months and would cover long term illness such as cancer and HIV or mental health problems Yes No
EQUAL OPPORTUNITIES MONITORING Date of Birth Gender Male Female Transgender Prefer not to say Ethnicity WHITE English Scottish Welsh Irish British Other If please Specify MIXED White and Black African White and Black Caribbean White and Asian Other If ‘Other’ please specify ASIAN or ASIAN BRITISH Indian Bangladeshi Pakistani Other If ‘Other’ please specify BLACK or BLACK BRITISH African Caribbean Other If ‘Other’ please specify ANY OTHER ETHNIC GROUP (please state) Sexual Orientation Bisexual Heterosexual Homosexual Prefer not to say Religious Beliefs Catholic (all) Christian (all) Muslim Hindu Judaism None If ‘Other’ please specify Do you consider yourself to have a disability as defined in current legislation? Under current legislation, a disability is defined as a physical or mental impairment that has a substantial an long-term adverse effect on his or her ability to carry out day to day activities. In this definition, long term is taken to mean more than twelve months and would cover long term illness such as cancer and HIV or mental health problems Yes No
EQUAL OPPORTUNITIES MONITORING Date of Birth Gender Male Female Transgender Prefer not to say Ethnicity WHITE English Scottish Welsh Irish British Other If ‘Other’ please Specify MIXED White and Black African White and Black Caribbean White and Asian Other If please specify ASIAN or ASIAN BRITISH Indian Bangladeshi Pakistani Other If ‘Other’ please specify BLACK or BLACK BRITISH African Caribbean Other If ‘Other’ please specify ANY OTHER ETHNIC GROUP (please state) Sexual Orientation Bisexual Heterosexual Homosexual Prefer not to say Religious Beliefs Catholic (all) Christian (all) Muslim Hindu Judaism None If ‘Other’ please specify Do you consider yourself to have a disability as defined in current legislation? Under current legislation, a disability is defined as a physical or mental impairment that has a substantial an long-term adverse effect on his or her ability to carry out day to day activities. In this definition, long term is taken to mean more than twelve months and would cover long term illness such as cancer and HIV or mental health problems Yes No
Name____________________________________________Section_____________ How to Create a WC Page in Noodletools 1. Sign in to Noodletools. 2. on your project. 3. Click on Works Cited under Components. 4. Locate the printer icon next to the words “Print/Export.” Click on the arrow & select “Print/Export to Word” from the drop down list. 5. Open your “Works Cited” page (from the bottom taskbar) & click the “Enable Editing” button. 6. Go to the File ribbon & choose “Save As” to save your WC Page. 7. The cursor should be to the left of the “Works Cited.” Hit Enter once. 8. Place the cursor above the “Works Cited” title. 9. Now you need to change the top margin from 1 inch to .5 inches. Go to the Page Layout ribbon & click on the small downward arrow to the right of “Page Setup.” This opens to the margin tab where you click on the down arrow for the Top margin to reduce the 1 inch margin to .5. 10. Go to the Home ribbon & click on “Align Text Right.” 11. Type your last name & the page number. 12. Click Save again & check to be sure that your sources are listed in alpha- betical order & that your WC Page’s format looks like the sample below. Sampras 3 Works Cited "Medical Marijuana in Plant Form Should Not Be Legalized." Drug Legalization. Ed. Noël Merino. Farmington Hills, MI: Greenhaven Press, 2015. Current Controversies. Rpt. from "Sample Testimony About Medical Marijuana from Massachusetts." Vol. 1. 2013. Opposing Viewpoints in Context. Web. 27 Feb. 2016. Morgan, Kayla. Legalizing Marijuana. Edina: ABDO, 2011. Print. Ross, Winston. "The High Road." Newsweek Global 162.1 (2014): 80. Points of View Reference Center. Web. 27 Feb. 2016.
0.1 29th Aug 2013 First Draft Raj Saket Madan Dhananjay Kumar 1.0 30th Sep 2013 Approved and Baselined Rahul Raj Dhananjay Kumar Ajay Kumar Zalpuri 1.1 29th July 2015 Update Clause 6.1 included for Business process & Operation process. Update in section 6.9 Risk Treatment Plan for project duration for risk mitigation Rahul raj Dhananjay Kumar Ajay Kumar Zalpuri 2.0 112th May 2016 Update section 4, 5, 6, 6.2, 6.3, 6.9 & 6.10 Rahul Raj SEPG Team Ajay kumar Zalpuri Table of Contents
EUROPEAN POOMSAE TEAM – GREECE 2017 U14 Male Nino Ontoy Manx U14 Female Natasha Wilson Central U17 Male Jack Durcan Shins U17 Female Emily Hoang Nomad U30 Male Henry Chiu Livingwell U30 Female Emily Whiting Livingwell U40 Male Said Khelwatty LTA U40 Female Wenqi Li PremierKi U50 Male Simon Negus PremierKi U50 Female Claire Spowart Central U60 Male Ali Pourtaheri Dragons Den U60 Male Yousuf Dildar LTA U65 Male Peter Johnson Stoke U65 Female Angela Broadbent Shins +66 Male Mike Pejic 18+M Freestyle Erol Ismail Golden Eagle U14 Pair U17 Pair Tahya Fells Kang Han Joshua Streetwise Emily Hoang Nomad Maximo Libid PremierKi U30 Pair 31+ Pair Emily Whiting Livingwell Henry Chiu Livingwell Wenqi Li PremierKi Negus PremierKi U14 Team Female Rebecca Fletcher Streetwise Fells Kang Han Nguyen- Harrison Allen TKD U14 Team Male Oluwatimilehin Akinrele - Nomad Joshua Tobin Streetwise Nino Ontoy Manx U17 Team Male Jack Britton Maximo Hiren Visrolia
Streetwise PremierKi Nomad U30 Team Male James Barrett Carlton Arena Thomas Leatherland Carlton Arena Cameron Park Koryo 31+ Team Female Claire Howard Streetwise Lyndzie Jeffrey Granite City Claire Spowart Central U14 Pair – Presidents Cup Qualification Natasha Wilson Central Ciaran Mein Cenral OFFICIALS Head of Team Mark Abberley Head Coach 41+ Coach U30/40M Coach U30/40F Gemma Biescas Chi Lai Dave Morrison Coach U17 Coach U14M Coach U14F David Bailey Sang Young Park Chan Sau
EUROPEAN POOMSAE TEAM – GREECE 2017 U14 Male Nino Manx U14 Female Natasha Wilson Central U17 Male Jack Durcan Shins U17 Female Emily Hoang U30 Male Henry Chiu Livingwell U30 Female Emily Whiting Livingwell U40 Male Said Khelwatty LTA U40 Female Wenqi Li PremierKi U50 Male Negus PremierKi U50 Female Claire Spowart Central U60 Male Ali Pourtaheri Dragons Den U60 Male Yousuf Dildar LTA U65 Male Peter Johnson Stoke U65 Female Angela Broadbent Shins +66 Male Mike Pejic Pejic 18+M Freestyle Erol Ismail Golden Eagle U14 Pair U17 Pair Tahya Fells Kang Han Joshua Tobin Streetwise Emily Hoang Nomad Maximo Libid PremierKi U30 Pair 31+ Pair Emily Whiting Livingwell Henry Chiu Livingwell Wenqi Li PremierKi Simon Negus PremierKi U14 Team Female Rebecca Fletcher Streetwise Fells Kang Han Donna Ngyuen- Harrison Allen TKD U14 Team Male Oluwatimilehin Akinrele - Joshua Tobin Streetwise Nino Ontoy Manx U17 Team Male Jack Britton Maximo Libid Visrolia
Streetwise PremierKi Nomad U30 Team Male James Barrett Carlton Arena Thomas Leatherland Carlton Arena Cameron Park Koryo 31+ Team Female Claire Howard Streetwise Lyndzie Jeffrey Granite City Claire Spowart Central U14 Pair – Presidents Cup Qualification Natasha Wilson Central Ciaran Mein Cenral OFFICIALS Head of Team Mark Abberley Head Coach 41+ Coach U30/40M U30/40F Biescas Chi Lai Dave Morrison Coach U17 Coach U14M Coach U14F Bailey Sang Young Park Chan Sau
Password Policy Version History: Ver. Date Description of Change Authored / Revised By Reviewed By Approved By 1.0 11th June, 2012 Draft 1.1 10th July, 2012 Initial Version Ajeet Saket GM Dua 2.0 17th Aug, 2012 Update section 5.0 Ajeet Saket GM Dua 2.1 15th Oct 2012 Update section 4.0 Ajeet Saket Ajay Kumar zalpuri 2.2 28th Feb 2014 Update section 4.0 for Password string definition & default password setting for new joining Ajeet Saket Ajay Kumar Zalpuri
The purpose of this MoU is to set out the agreed arrangements that will be pursued by the Commonwealth and the Northern Territory to deliver a for environmental approvals under the Environment Protection and Biodiversity Conservation Act 1999 (EPBC Act) removing duplication in assessment and approvals processes, while maintaining environmental outcomes. This MoU is not a legal agreement. However, both Parties commit to using their best endeavours to achieve its purpose. Objects The objects of the assessment and approvals agreements will be to: Ensure high standards are maintained for the protection of the environment and, in particular, matters of national environmental significance (NES); Promote the conservation and ecologically sustainable use of natural resources; Ensure an efficient, timely and effective process for environmental assessment and approval of actions; and Remove unnecessary duplication in the environmental assessment and approvals processes of the Commonwealth and the Northern Territory. Roles Consistent with the objects of this MoU, the Northern Territory will become responsible for assessing projects for the purpose of the EPBC Act to reduce duplication between jurisdictions, and - within 12 months - approving projects, when an approval bilateral agreement has been signed. Consistent with the objects of this MoU, the Commonwealth will take a more strategic approach to environmental protection and assurance when an approval bilateral agreement has been signed. Provisions 1. Parties 1.1.1 The Parties to this MoU are the: Commonwealth of Australia represented by the Prime Minister and the Commonwealth Minister for the Environment (Commonwealth); and
TBBT0258 YOUNGS BLOCK TENNANT CREEK TBVR0466 YUBULYAWUN ALT (NTP4058) KATHERINE THAS0105 YUENDUMU SPRINGS TEAS0417 BLOCK ALICE SPRINGS TEDG0852 ZEN RANCH DARWIN TGVR0502 ZISWILER ON KATHERINE Darwin Region Fax: 08 8999 2146 Veterinary Officer Ph: 08 8999 2035 M: 0427 003 600 Regional Livestock Biosecurity Officer (RLBO) Ph: 08 8999 2034 M: 0401 115 802 Livestock Biosecurity Officer (LBO) Ph: 08 8999 2030 M: 0409 736 235 Katherine Region Fax: 08 8973 9759 Veterinary Officer (FVO) Ph: 08 8973 9716 M: 0437 527 372 Regional Livestock Biosecurity Officer (RLBO) Ph: 08 8973 9767 M: 0467 740 233 Livestock Biosecurity Officer (LBO) Ph: 08 8973 9765 M: 0427 604 002 Tennant Region Fax: 08 8962 4480 Principal Livestock Biosecurity Officer (PLBO) Ph: 08 8962 4458 M: 0401 113 445 Livestock Biosecurity Officer (LBO) Ph: 08 8962 4492 M: 0457 517 347 Alice Springs Region Fax: 08 8951 8123 Senior Field Veterinary Officer (SFVO) Ph: 08 8951 8181 M: 0401 118 181 Regional Livestock Biosecurity Officer (RLBO) Ph: 08 8951 8125 M: 0401 118 125 Renae McLean – Principal Livestock Regulatory Officer (PLRO) Ph: 08 8973 9703 | M: 0448 441 915 | E-mail: renae.mclean@nt.gov.au Adele Kluth - Livestock Identification Systems Administrator (LISA) / Brands Ph: 08 8999 2033 | E-mail: adele.kluth@nt.gov.au Postal Address: BAW DPIR, GPO Box 3000, Darwin NT 0801 Brand and identify livestock NT Brands Register – Search Database NT Property Identification Code (PIC) Search
Ph: 08 8999 2030 M: 0409 736 235 Ph: 08 8973 9765 M: 0427 604 002 Tennant Creek Region Fax: 08 8962 4480 Principal Livestock Biosecurity Officer (PLBO) Ph: 08 8962 4458 M: 0401 113 445 Livestock Biosecurity Officer (LBO) Ph: 08 8962 4492 M: 0457 517 347 Springs Region Fax: 08 8951 8123 Senior Field Veterinary Officer (SFVO) Ph: 08 8951 8181 M: 0401 118 181 Regional Livestock Biosecurity Officer (RLBO) Ph: 08 8951 8125 M: 0401 118 125 Renae McLean – Principal Livestock Regulatory Officer (PLRO) Ph: 08 8973 9703 | M: 0448 441 915 | E-mail: renae.mclean@nt.gov.au Adele Kluth - Livestock Identification Systems Administrator (LISA) / Brands Ph: 08 8999 2033 | E-mail: adele.kluth@nt.gov.au Postal Address: BAW DPIR, GPO Box 3000, Darwin NT 0801 Brand and identify livestock NT Brands Register – Search Database NT Property Identification Code (PIC) Search
2012 Peterbilt 587 SPECS Condition: Used Stock #: NT4014 Year: 2012 Make: Peterbilt Model: 587 Cab: 70” Raised Roof Engine: Cummins ISX MILEAGE: 501,000 Miles Horsepower: 450 Fuel Type: Diesel Transmission: 13 Spd Suspension: Air Ride Tires: Wheels: All Aluminum Wheelbase: 236 in # Rear AXLES: Tandem VIN: 1XP4D49X6CD125965 ISLAND, NE 4747 Juergen Road (308) 384-0130 NORTH PLATTE, NE 2502 East 4th Street (308) 532-7730 www.NebraskaTruck.com
David Williams, Paul’s Metaphors (Hendrickson, 2003) ISBN 978-1-5656-3984-3 Herman Ridderbos, Paul: An Outline of His Theology (Eerdmans, 1997) ISBN: 978-0-8028-4469-9 Assessment 10% Review of the first two chapters of Ridderbos due September 27th 10% Summary of 12 Metaphors (1 each chapter) due October 25th 50% Final exam - due two weeks after last class (i.e. Nov 10th) 30% Research Paper; due four weeks after last class (i.e. Nov24th) When is the Course being Run? Tuesday 6-9PM, February 07 - May 08 General Outline # Date Class Lectures 1 Sept 21-22 The Center of Paul? & Romans 2 Sept 28-29 Romans, Galatians, Colossians, Ephesians, Philippians(?) 3 Oct 19-20 Philippians, 1&2Thessalonians, 1Corinthians 4 Oct 26-27 1&2 Corinthians, Pastorals, Review Course Objectives Related to MDiv* Student Learning Outcomes MDiv* Student Learning Outcomes Rubric Mini-Justification
This application was provisionally approved by consensus, subject to the following information being received. Please amend the information sheet and consent form, taking into account the suggestions made by the Committee (Ethical Guidelines for Intervention Studies para 6.22). Please provide age appropriate information sheets and assent forms for younger participants and amend the existing information sheets and assent/consent form, taking into account the suggestions made by the Committee (Ethical Guidelines for Intervention Studies para 6.22). Provide further information on the study design, in particular the unblinding procedures (Ethical Guidelines for Intervention Studies para 5.41) This following information will be reviewed, and a final decision made on the application, by Dr Christine Crooks and Dr Brian Fergus. 3 Ethics ref: 15/NTA/195 Title: Safety and efficacy of ziv Aflibercept compounding in refractory diabetic macular oedema Principal Investigator: Dr Andrew Riley Sponsor: Clock Start Date: 19 November 2015 Dr Andrew (CI) and Ms Sarah Welsh were present in person for discussion of this application. Potential conflicts of interest The asked members to declare any potential conflicts of interest related to this application. No potential conflicts of interest related to this application were declared by any member. Summary of Study The study investigates study drug in refractory diabetic macular oedema (a leading cause of blindness in patients with diabetes). The Researcher(s) explained the treatment options available to patients, emphasising the very high cost of current best available treatment. The cost is unsustainable limits its use for care. This protocol uses compounding to reduce the costs from $2k per injection to $113 per injection. This will enable more patients to be treated. Thus, the drug will make treatment more accessible, and potentially increase length of time between required visits. The study involves off label use of a drug (Aflibercept) which has an efficacy profile superior to the current standard treatment in New Zealand. The Researcher(s) confirmed this is a pilot to test an effective drug using a different formulation (compounded). The researchers have used the compounding process for a similar drug in a similar research setting which has become standard practice. Summary of ethical issues (resolved) trial
How are the following CFR court personnel selected for their positions? (Select all that apply.) Appointed Elected Hired Under Contract as a BIA Employee a. Court administrator b. Clerk of the court During 2013, did your CFR court employees receive training in any of the following areas? (Select all that apply.) a. The Indian Child Welfare Act b. The Violence Against Women Act c. Funding opportunities/Grant writing d. Criminal justice database submission or reporting e. Domestic violence protection registry or database development f. Responding to domestic violence, physical assault and/or sexual assault cases g. No training was received. h. Other: (Please describe) During 2013, did your CFR court receive technical assistance in any of the following areas? (Select all that apply.) a. Tribal code development b. Sex offender registry development or management c. Domestic violence case management d. No technical assistance was received e. Other: (Please describe) Does your tribal court rely on state courts for any judicial services? a. Yes b. No Does your tribal court rely on county or local government social service agencies for treatment in juvenile and/or family cases? a. Yes b. No Section B. Appellate System DIRECTIONS: For survey items requesting case count information, please provide the total number of cases closed by your CFR court during the calendar year 2013. Use the following definition to determine case numbers: A case is a set of all charges against a single defendant that the court handles as a single matter. A case with three defendants should be counted as three cases, but a case with one defendant with multiple charges should be counted as one case. NOTE: If you are unable to provide the actual case count number, please provide your best estimate and check the “Check here if this is an estimate” checkbox. If the case count is none, enter “0” as your answer. If you do not track this information, please check the “Do not track these case numbers” checkbox. Does your justice system have a court of appeals or participate in an intertribal appellate court? a. Yes (Please provide the official name of the court of appeals. For example: Indian Court of Appeals) b. No (GO TO SECTION C) of the following components does your tribal appellate court procedure contain? (Select all that apply.) a. Filing a notice of appeal b. Filing a transcript of proceedings
Committee: Northern A Health and Disability Ethics Committee Meeting date: 10 May 2016 Meeting venue: Novotel Ellerslie, 72-112 Greenlane Rd East, Ellerslie, Auckland Time Item of business 1.00pm Welcome 1.05pm Confirmation of minutes of meeting of 12 April 2016 New applications (see over for details) 1.30-1.55 1.55-2.20 2.20-2.45 2.45-3.10 3.10-3.35 3.35-4.00 4.00-4.25 4.25-4.50 4.50-5.15 i 16/NTA/61 ii 16/NTA/55 iii 16/NTA/54 iv 16/NTA/56 v 16/NTA/57 vi 16/NTA/60 vii 16/NTA/58 viii 16/NTA/63 ix 16/NTA/64 5.15pm 5.30pm General business: Noting section Optional HDEC member training module 6.00pm Meeting ends Member Name Member Category Appointed Term Expires Dr Brian Fergus Lay (consumer/community perspectives) 11/11/2015 11/11/2018 Present Ms Buckland Lay (consumer/community perspectives) 11/11/2015 11/11/2016 Present Dr Karen Bartholomew Non-lay (intervention studies) 01/07/2013 01/07/2016 Present Dr Christine Crooks Non-lay (intervention studies) 11/11/2015 11/11/2018 Present Ms Shamim Chagani Non-lay (health/disability service provision) 11/11/2015 11/11/2016 Present Dr Kate Parker Lay (consumer/community perspectives) 11/11/2015 11/11/2018 Present Dr Charis Brown Non-lay (intervention studies) 11/11/2015 11/11/2018 Apologies Ms Rosemary Abbott Lay (the law) 15/03/2016 15/03/2019 Present Trial
Committee: Northern A Health and Disability Ethics Committee Meeting date: 10 November 2015 Meeting venue: Novotel Ellerslie, 72-112 Greenlane Rd East, Auckland Time Item of business 1.00pm Welcome 1.05pm Confirmation of minutes of meeting of 13 October 2015 and 21 October 2015. 1.30pm New applications (see over for details) 1.30-1.55 1.55-2.20 2.20-2.45 2.45-3.10 3.10-3.35 3.35-4.00 4.00-4.25 4.25-4.50 4.50-5.15 5.15-5.40 5.40-6.05 6.05-6.30 i 15/NTA/168 ii 15/NTA/169 iii 15/NTA/170 iv 15/NTA/171 v 15/NTA/172 vi 15/NTA/173 vii 15/NTA/174 viii 15/NTA/175 ix 15/NTA/176 x 15/NTA/183 xi 15/NTA/184 xii 15/NTA/185 6.30pm General business: Noting section of agenda 6.30pm Meeting ends Member Name Member Category Appointed Term Expires Apologies? Dr Brian Fergus Lay (consumer/community perspectives) 01/07/2012 01/07/2015 Present Ms Susan Buckland Lay (consumer/community perspectives) 01/07/2012 01/07/2015 Present Mr Kerry Hiini Lay (consumer/community perspectives) 01/07/2012 01/07/2015 Present Dr Karen Bartholomew Non-lay (intervention studies) 01/07/2013 01/07/2016 Apologies Dr Christine Crooks Non-lay (intervention studies) 01/07/2013 01/07/2015 Present Mr Mark Smith Non-lay (intervention studies) 01/09/2014 01/09/2015 Apologies Mrs Kate O'Connor Present Ms Shamim Chagani Non-lay (health/disability service provision) 01/07/2012 01/07/2015 Present Welcome
Committee: Northern A Health and Disability Ethics Committee Meeting date: 11 August 2015 Meeting venue: Novotel Ellerslie Time Item of business 1.00pm Welcome 1.00pm Confirmation of minutes of meeting of 14 July 2015 New applications (see over for details) 1.30pm i 15/NTA/93 ii 15/NTA/97 iii 15/NTA/98 iv 15/NTA/101 v 15/NTA/102 vi 15/NTA/103 vii 15/NTA/104 viii 15/NTA/105 ix 15/NTA/106 x 15/NTA/107 xi 15/NTA/108 6.30pm General business: Noting section of agenda 6.45pm Meeting ends Member Name Member Category Appointed Term Expires Apologies? Dr Brian Fergus Lay (consumer/community perspectives) 01/07/2012 01/07/2015 Present Ms Susan Buckland Lay (consumer/community perspectives) 01/07/2012 01/07/2015 Present Mr Kerry Hiini Lay (consumer/community perspectives) 01/07/2012 01/07/2015 Present Ms Michele Stanton Lay (the law) 01/07/2012 01/07/2015 Present Dr Karen Bartholomew Non-lay (intervention studies) 01/07/2013 01/07/2016 Present Dr Christine Crooks Non-lay (intervention studies) 01/07/2013 01/07/2015 Present Mr Mark Non-lay (intervention studies) 01/09/2014 01/09/2015 Present Ms Shamim Chagani Non Lay (intervention studies) 01/07/2013 01/07/2015 Present Welcome The Chair opened the meeting at 1.05pm and welcomed Committee members.
Committee: Northern A Health and Disability Ethics Committee Meeting date: 12 August 2014 Meeting venue: Novotel Ellerslie, 72-112 Greenlane Rd East, Ellerslie, Auckland Time Item of business 1.00pm Welcome 1.05 Confirmation of minutes of meeting of 08 July 2014 New applications (see over for details) 1.30-2.00 2.00-2.30 2.30-3.00 3.00-3.30 3.30-4.00 4.00-4.30 4.30-5.00 5.00-5.30 i 14/NTA/111 ii 14/NTA/112 iii 14/NTA/113 iv 14/NTA/115 v 14/NTA/116 vi 14/NTA/118 vii 14/NTA/119 (Closed) viii 14/NTA/123 5.30-5.45 General business: Noting section of agenda 6.00 Meeting ends Member Name Member Category Appointed Term Expires Apologies? Dr Brian Fergus Lay (consumer/community perspectives) 01/07/2012 01/07/2015 Present Ms Buckland Lay (consumer/community perspectives) 01/07/2012 01/07/2015 Present Ms Shamim Chagani Non-lay (health/disability service provision) 01/07/2012 01/07/2015 Present Mr Hiini Lay (consumer/community perspectives) 01/07/2012 01/07/2015 Present Dr Etuate Saafi Non-lay (intervention studies) 01/07/2012 01/07/2014 Present Ms Michele Stanton Lay (the law) 01/07/2012 01/07/2015 Present Dr Karen Bartholomew Non-lay (intervention studies) 01/07/2013 01/07/2016 Present
This application was provisionally approved by consensus, subject to the following information being received. Please provide evidence of favourable independent peer review of the study protocol (Ethical Guidelines for Intervention Studies Appendix 1). Please amend the information sheet and consent form, taking into account the suggestions made by the Committee (Ethical Guidelines for Intervention Studies para 6.22). This following information will be reviewed, and a final decision made on the application, by Dr Nicola Swain and Ms Rochelle Style 5 Ethics ref: 17/NTA/254 Title: EVOLVE 48 Study Principal Investigator: Dr Seif El-Jack Sponsor: Boston Scientific Corporation Clock Start Date: 30 November 2017 Hector Gonzales was present in person for discussion of this application. Potential conflicts of interest The Chair asked members to declare any potential conflicts of interest related to this application. No potential conflicts of interest related to this application were declared by any member. Summary of Safety and efficacy of the SYNERGY Stent System has been demonstrated in the EVOLVE Clinical Program. The SYNERGY has unique characteristics, and is designed to complete resorption of the polymer shortly following the drug elution at 90 days. The EVOLVE 48 is designed to assess the safety and effectiveness of the SYNERGY 48 mm Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) > 34 mm and ≤ 44 mm in length (by visual estimate) in native coronary arteries ≥2.5 mm to ≤4.0 mm in diameter (by visual estimate). Sites outside the United States (US) are being included in this protocol to collect additional 48 mm data to support future FDA approval. This is also an opportunity to collect EU safety and performance data for the current CE Marked 48 mm device. Summary of ethical issues (outstanding) The main ethical issues considered by the Committee and which require addressing by the Researcher are as follows. The Committee noted that insurance provided must be available at equivalent levels to ACC, and must be accessible. Please review chapter 8 of the National Ethics Advisory Committee Ethical guidelines for Intervention Studies and respond to the Committee confirming those ethical standards are met. The Committee requested the following changes to the Participant Information Sheet and Consent Form:
Committee: Northern A Health and Disability Ethics Committee Meeting date: 06 December 2016 Meeting venue: Novotel Ellerslie, 72-112 Greenlane Rd East, Ellerslie, Auckland Time Item of business 1.00pm Welcome 1.05pm 1.30pm Confirmation of minutes of meeting of 15 November 2016 Review of approved studies (see over for details) I 13/NTA/100 New applications (see over for details) 1.00pm 6.30pm i 16/NTA/197 ii 16/NTA/199 iii 16/NTA/200 iv 16/NTA/202 v 16/NTA/203 vi 16/NTA/204 vii 16/NTA/205 viii 16/NTA/208 ix 16/NTA/209 x 16/NTA/211 xi 16/NTA/215 General business: Noting section of agenda 6.30pm Meeting ends Member Name Member Category Appointed Term Expires Apologies? Dr Brian Fergus Lay (consumer/community perspectives) 11/11/2015 11/11/2018 Present Dr Karen Bartholomew Non-lay (intervention studies) 13/05/2016 13/05/2019 Present Dr Christine Crooks Non-lay (intervention studies) 11/11/2015 11/11/2018 Present Dr Kate Parker Non-lay (observational studies) 11/11/2015 11/11/2018 Apologies Dr Charis Brown Non-lay (observational studies) 11/11/2015 11/11/2018 Present Ms Rosemary Abbott Lay (the law) 15/03/2016 15/03/2019 Apologies Mrs Leesa Russell Non-lay (observational studies) NTB Co-opt NTB Co-opt Present Dr Catherine Jackson Non-lay (health/disability service provision) 11/11/2016 11/11/2019 Present Ms Toni Millar Lay (consumer/community perspectives) 11/11/2016 11/11/2019 Present Dr Angela Ballantyne Lay (ethical and reasoning) CEN Co-opt CEN Co-opt Present trial
Please combine consent forms into a single document. Please lay out exactly what participants are consenting to in a clear manner. Decision This application was provisionally approved by consensus subject to the following information being received. Please amend the information sheet and consent form, taking into account the suggestions made by the Committee (Ethical Guidelines for Intervention Studies para 6.22). This following information will be reviewed, and a final decision made on the application, by Dr Charis Brown and Mr John Hancock. 6 Ethics ref: 16/NTA/113 Title: Treatment of mild-moderate Impetigo Principal Investigator: Dr Alison Leversha Sponsor: Clock Start Date: 28 July 2016 Dr Alison Leversha was present in person for discussion of this application. Potential conflicts of interest The Chair asked members to declare any potential conflicts of interest related to this application. Dr Karen Bartholomew declared a potential conflict of interest, and the Committee decided to allow her to remain present, but not participate in the discussion or decision making processes. Summary of Study The aims to add screening for impetigo onto an already extant rheumatic fever screening process in place in low decile schools. They will assess the efficacy of standard wound care versus that of an antibiotic cream. The schools and students are familiar with the screening process and were concerned about skin infections as rheumatic fever rates have been found to be low. The Committee asked for incidence rates of impetigo. The CI explained that around 25% of children will have skin infections. Summary of ethical issues (resolved) The main ethical issues considered by the Committee and addressed by the Researcher are as follows. The Committee queried how consent would be obtained. The Ci explained that parents consent for their child when their child goes to school. If any form of treatment is required then they call the parents and seek consent. The Committee asked how parents wanting to time to think about their choices would be managed. The Ci explained that parents will be able to think about this overnight. Parents coming into the school to collect medicine will be able to discuss with staff.
Committee: Northern A Health and Disability Ethics Committee Meeting date: 09 February 2016 Meeting venue: Novotel Ellerslie, 72-112 Greenlane Rd East, Ellerslie, Auckland Time Item of business 1.00pm Welcome 1.05pm Confirmation of minutes of meeting of 01 December 2015 New applications (see over for details) i 15/NTA/206 ii 16/NTA/6 iii 16/NTA/10 1.25pm General business: Noting section of agenda 1.30pm Meeting ends Member Name Member Category Appointed Term Expires Apologies? Dr Brian Fergus Lay (consumer/community perspectives) 01/07/2012 01/07/2015 Present Ms Susan Buckland Lay (consumer/community perspectives) 01/07/2012 01/07/2015 Present Dr Karen Bartholomew Non-lay (intervention studies) 01/07/2013 01/07/2016 Present Dr Christine Crooks Non-lay (intervention studies) 01/07/2013 01/07/2015 Present Ms Shamim Chagani Non-lay (health/disability service provision) 01/07/2012 01/07/2015 Present Dr Kate Parker Lay (consumer/community perspectives) 11/11/2015 11/11/2018 Present Dr Charis Non-lay (intervention studies) 11/11/2015 11/11/2018 Present Welcome The Chair opened the meeting at 1.00pm and welcomed Committee members. The Chair noted that the meeting was quorate. The Committee and agreed the agenda for the meeting. trial
give consent themselves. Mr Kepple noted that the researchers considered this group an important one that would also need protection and stated that any sensitive issues such as the pregnancy aspect will need to be considered carefully. The committee asked that the researchers provide it with information on how the researchers intend to handle the 13-16 year olds who are unable to give consent. Mr Kepple advised that the consultation process is ongoing and the committee requested evidence once the process is completed. The committee confirmed that an indemnity certificate was included with the application. The committee asked what restrictions the research team intended to place on the publication of study results and also that the research team record their interpretation of what the researchers have agreed with the sponsor and provide this record to the committee. The committee noted that there is no data safety monitoring committee (DSMC) for this trial and asked how the researchers intended to stop the study if a DSMC is not in place. Mr Kepple advised that standard data monitoring is being conducted. The committee sought further clarification about who will make the decision to stop the study and how will it be made. Mr Kepple advised a sponsor and medical monitor assigned by the sponsor will make the decision. Participant Information Sheet and Consent Form Please make the language more understandable to a New Zealand audience. Please include the information storage and destruction of human tissue given at r3.7 on the application form in the participant information sheet Page 9 ‘Are there other influenza medications? Please add “if you do not want to be part of this study” to the first sentence. Decision This application was provisionally approved by consensus, subject to the following information being received. The Committee requires information on how you intend to advise and protect the 13-16 year olds who are unable to give consent to take part in this study. Please amend the information sheet and consent form, taking into account the suggestions made by the Committee (Ethical Guidelines for Intervention Studies para 6.22). This information will be reviewed, and a final decision made on the application, by the Chair Etuate and Shamim. 4 Ethics ref: 13/NTA/74 Title: therapy to support the well-being of young people with intellectual disability Principal Investigator: Dr Daphne J. Rickson Sponsor: IHC Foundation Clock Start Date: 27 May 2013 Dr Daphne Rickson was present by teleconference for discussion of this application. trial
business costs #2 (Worst Case) Base + Spillover (No Offsetting Gains) Scenario 1 plus workers earning in 2014 will also benefit A. $493 million increase Workers’ Wages* B. $531 million increase in business costs # 3 Base + Spillover + Productivity Scenario 2 plus businesses offset 30% of the increase in costs due to increased productivity A. $493 million increase Workers’ Wages* B. $372 million increase in business costs # 4 (Most Likely Case) Base + Spillover + Productivity + Consumption Scenario 3 plus wage gainers will all of their additional income on consumption A. $493 million increase Workers’ Wages*; B. 0.150%, increases in consumption by DC residents** C. $372 million increase in business costs. # 5 (Best Case) Base + Spillover + Consumption + Efficiency Wage Scenario 4 plus offset 75% of the increase in costs due to increased productivity and other efficiencies A. $493 million increase Workers’ Wages*; B. 0.150%, increases in consumption by DC residents** C. $80 million